|
NFKBIL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.16889999901559E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.92070000015754E-07 |
| Normal-vs-Stage2 |
2.570000E-04 |
| Normal-vs-Stage3 |
4.03479999966372E-07 |
| Normal-vs-Stage4 |
6.52889999841477E-08 |
| Stage1-vs-Stage2 |
8.752400E-01 |
| Stage1-vs-Stage3 |
5.441600E-01 |
| Stage1-vs-Stage4 |
2.395200E-01 |
| Stage2-vs-Stage3 |
8.053600E-01 |
| Stage2-vs-Stage4 |
5.216800E-01 |
| Stage3-vs-Stage4 |
6.017600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.24740000054346E-07 |
| Normal-vs-AfricanAmerican |
4.982200E-02 |
| Normal-vs-Asian |
1.06390000031986E-07 |
| Caucasian-vs-AfricanAmerican |
5.336000E-01 |
| Caucasian-vs-Asian |
2.761000E-01 |
| AfricanAmerican-vs-Asian |
3.002600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.555100E-04 |
| Normal-vs-Female |
6.9967998062026E-10 |
| Male-vs-Female |
2.407800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.03009999996573E-06 |
| Normal-vs-Age(41-60Yrs) |
1.62600000130908E-08 |
| Normal-vs-Age(61-80Yrs) |
7.559800000001E-05 |
| Normal-vs-Age(81-100Yrs) |
8.179500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.657600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.566000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.665200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.451180E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.248600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.319400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.713800E-02 |
| Classical-VS-Follicular |
9.719700E-02 |
| Classical-VS-Other |
4.848600E-01 |
| Classical-VS-Normal |
3.01950000003437E-07 |
| Tall-VS-Follicular |
8.242200E-01 |
| Tall-VS-Other |
3.049400E-01 |
| Tall-VS-Normal |
2.95070001765652E-09 |
| Follicular-VS-Other |
3.281600E-01 |
| Follicular-VS-Normal |
6.54789999998684E-08 |
| Other-VS-Normal |
7.907000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.47489999955542E-07 |
| Normal-vs-N1 |
4.93529994649577E-09 |
| N0-vs-N1 |
2.217700E-02 |
|
|
